Valsartan
- All
- News
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Indian Medicine Firm Pulls Heart Drug From US Amid Cancer Risk Probes
A unit of India's Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.
-
China Directs Medical Institutions To Not Use Recalled Huahai-Made Drug
China's health regulator said on Monday all domestic medical institutions must cooperate with authorities and not use the valsartan blood and heart drug made by Zhejiang Huahai Pharmaceutical that could pose cancer risks.
-
Novartis Japan Hit With Suspension Over Side-Effect Reporting
Japanese health authorities said today that they have ordered the local unit of Swiss pharmaceutical giant Novartis to temporarily suspend its operations for failing to report drug side effects.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Indian Medicine Firm Pulls Heart Drug From US Amid Cancer Risk Probes
A unit of India's Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.
-
China Directs Medical Institutions To Not Use Recalled Huahai-Made Drug
China's health regulator said on Monday all domestic medical institutions must cooperate with authorities and not use the valsartan blood and heart drug made by Zhejiang Huahai Pharmaceutical that could pose cancer risks.
-
Novartis Japan Hit With Suspension Over Side-Effect Reporting
Japanese health authorities said today that they have ordered the local unit of Swiss pharmaceutical giant Novartis to temporarily suspend its operations for failing to report drug side effects.
